Efficacy and Safety of an Intravenous C1-Inhibitor Concentrate for Long-Term Prophylaxis in Hereditary angioedema

Efficacy and Safety of an Intravenous C1-Inhibitor Concentrate for Long-Term Prophylaxis in Hereditary angioedema

Background The plasma-derived, pasteurized, nanofiltered C1-inhibitor concentrate (pnfC1-INH) is approved in the United States as an intravenous (IV) on-demand treatment for hereditary angioedema (HAE) attacks, and, in Europe, as on demand and short-term prophylaxis. Objective This analysis evaluate...

Full description

Bibliographic Details
Main Authors: Timothy Craig D.O., Ralph Shapiro M.D., Arthur Vegh M.D., James W. Baker M.D., Jonathan A. Bernstein M.D., Paula Busse M.D., Markus Magerl M.D., Inmaculada Martinez-Saguer M.D., Marc A. Riedl M.D., William Lumry M.D., Debora Williams-Herman M.D., Jonathan Edelman M.D., Henrike Feuersenger Ph.D., Thomas Machnig M.D., Mikhail Rojavin Ph.D.
Format: Article
Language:English
Published: SAGE Publishing 2017-03-01
Series:Allergy & Rhinology
Online Access:https://doi.org/10.2500/ar.2017.8.0192

Internet

https://doi.org/10.2500/ar.2017.8.0192

Similar Items